For four decades, a single 1984 paper shaped how pediatricians, dietitians, and — more recently — health-tech founders built products for childhood obesity. That foundation just cracked.
New research led by Professor Andrew Agbaje, a physician and associate professor of clinical epidemiology and child health at the University of Eastern Finland, argues that the so-called 'adiposity rebound' — the rise in children's body mass index that begins around age 6 — is not a fat rebound at all. It is, according to Agbaje, largely the normal growth of muscle and lean tissue.
The study was presented at the European Congress on Obesity in Istanbul and published in The Journal of Nutrition.
What the old theory said
French researcher Marie Françoise Rolland-Cachera introduced the adiposity rebound concept in a 1984 paper in The American Journal of Clinical Nutrition. The theory: children whose BMI begins climbing again before age 5.5 face greater adiposity in adolescence than those whose rebound comes after age 7. Pediatricians treated the timing as a warning sign. Interventions followed.
What the new data shows
Agbaje analyzed data from 2,410 multiracial children aged 2–19 who participated in the US National Health and Nutrition Examination Survey (NHANES) 2021–2023 cycle. He compared BMI patterns against waist circumference-to-height ratio (WHtR), a measure that estimates body fat with around 90% accuracy compared to the gold-standard dual-energy X-ray absorptiometry.
Here is the key finding: average BMI at age 2 was 17.1 kg/m², declined, then returned to that same level by age 6 — appearing to confirm the classic rebound. But average WHtR at age 2 was 0.54, and children never returned to that level at age 6 or at any later point in childhood or adolescence. WHtR kept falling until about age 7, then rose — but never recovered to the age-2 baseline.
No fat rebound. The BMI pattern reflected lean tissue growth, not excess fat accumulation.
Agbaje also pointed to a randomized controlled trial in Finland that followed participants from 7 months to age 20. Children in an intervention group received a heart-healthy diet, dietary counseling, and nutrition education from infancy through early adulthood. The control group did not. Result: no difference in the average age at which BMI declined and then rose again.
'This is just one example showing clinical trials could not change the so-called adiposity rebound because it is simply a normal part of life and not a disease process or risk,' Agbaje said.
What it means for founders
The pediatric health and wellness market has been built, in part, on a framework that this research calls into question. Products targeting early BMI rebound as a risk signal — dietary apps, intervention programs, clinical decision tools — may be solving a problem that does not exist in the way the market assumed.
The math is simple: if the science moves, the regulatory and clinical environment moves with it, and the founders who built on the old framework face a repricing of their value proposition. The ones positioned to win are those building around direct fat-mass measurement, not BMI proxies.
Free markets correct faster than bureaucracies. The founders who read the data now have a head start.
